ExploreWatchlistsPricing
  1. JP-listed companies
  2. D.Western Therapeutics Institute, Inc.
  3. Financials
  4. Income before tax

D.Western Therapeutics Institute, Inc. (4576)

Market cap
¥4.9B
P/E ratio
-6.2x
De Western Therapeutics Institute develops protein kinase inhibitor drugs for eye diseases and licenses them to pharmaceutical companies for commercialization.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Dec 31, 2025-630-48.66%
Dec 31, 2024-1,228+54.21%
Dec 31, 2023-796+169.22%
Dec 31, 2022-296+85.21%
Dec 31, 2021-160-44.84%
Dec 31, 2020-290-364.22%
Dec 31, 2019110-113.75%
Dec 31, 2018-797+19.14%
Dec 31, 2017-669+119.70%
Dec 31, 2016-304+3.08%
Dec 31, 2015-295+54.09%
Dec 31, 2014-192-13.35%
Dec 31, 2013-221-13.31%
Dec 31, 2012-255-27.85%
Dec 31, 2011-354

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat